Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01985087 · ClinicalTrials.gov registry record · Phase 1

A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

A Phase 1 study of Glioblastoma, sponsored by University of Louisville.

Active
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT01985087: Active Phase 1 study of Glioblastoma, sponsored by University of Louisville.

NCT01985087 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by University of Louisville. The registered enrollment target is 18 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01985087, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by University of Louisville.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

In this study we propose to determine outcomes of patients age 70 or older treated with radiation over 2 weeks given with temozolomide 75 mg/m2 daily during radiotherapy and as a post radiation treatment of 150 mg/m2 - 200 mg /m2 for 6 cycles or until the disease progresses.

Primary Outcome

If \< 4 out of 10 patients in the initial analysis stop treatment due to toxicity it can proceed to phase II.

Conditions Studied

Glioblastoma

Interventions

  • DRUG Temozolomide
  • RADIATION Hypofractionated radiotherapy

Study Locations (1)

Kentucky

  • James Graham Brown Cancer Center - Louisville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2014-09
Est. Completion 2025-05
Phase Phase 1
University of Louisville

217 total trials

What the registry record for NCT01985087 still lists

NCT01985087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.

NCT01985087 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT01985087 about?

NCT01985087 is a clinical study titled "A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70". In this study we propose to determine outcomes of patients age 70 or older treated with radiation over 2 weeks given with temozolomide 75 mg/m2 daily during radiotherapy and as a post radiation treatment of 150 mg/m2 - 200 mg /m2 for 6 cycles or until the disease progresses.

What is the current status of trial NCT01985087?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-09. Estimated completion is 2025-05.

What conditions does trial NCT01985087 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT01985087?

The interventions under investigation include: Temozolomide (DRUG), Hypofractionated radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT01985087?

This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01985087 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01985087's enrollment target sits among peer trials

18 159th of 199 higher than 35 of 199 other Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01985087, the US trial registry maintained by the National Library of Medicine. NCT01985087 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.